Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data

CONCLUSION: Based on this initial experience at our center, pazopanib seems a feasible first-line treatment for mRCC due to its well-tolerable toxicity profile. However, larger data are required to confirm its efficacy in Indian patients.

Source: Indian Journal of Cancer - April 21, 2017 Category: Cancer & Oncology Authors: A Joshi V Agarwala A Ramaswamy V Noronha VM Patil S Menon P Popat N Sable K Prabhash Source Type: research